Altimmune (NYSE: ALT) — Company Overview, News & Financial Data
Altimmune is a biopharmaceutical company focused on treatments for respiratory diseases and immune-modulating therapies like vaccines.
Altimmune
Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing treatments that address critical needs in respiratory diseases and immune-modulating therapies. Their operations span the discovery, development, and commercialization of novel products to improve the lives of patients suffering from a range of conditions including obesity, liver diseases, and COVID-19. One of their flagship projects is a vaccine aimed at providing long-lasting protection against influenza, showcasing their commitment to tackling global health challenges. With a strategic approach to innovation and a dedicated team, Altimmune aims to advance its pipeline of promising candidates through the clinical stages, continually seeking to expand its impact on public health worldwide.
Snapshot
Operations
Products and/or services of Altimmune
- HepTcell, a therapeutic vaccine candidate for the treatment of chronic hepatitis B.
- AdCOVID, a single-dose intranasal vaccine candidate for COVID-19.
- T-COVID, an intranasal immunomodulator treatment for early COVID-19.
- ALT-801, a novel GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH).
- NasoShield, an anthrax vaccine candidate administered through a single intranasal dose.
- NasoVAX, an intranasal influenza vaccine candidate designed to provide long-lasting protection.
Altimmune executive team
- Jerome Benedict DursoChairman, CEO & President
- M. Scot RobertsChief Scientific Officer
- Christophe Arbet-EngelsChief Medical Officer
- Gregory L. WeaverChief Financial Officer
- Richard MenziusoVP, Global Controller & Principal Accounting Officer
- Bertrand GeorgesChief Technology Officer
- Luis SanayVice President of Investor Relations
- Tony BlandinVice President of Quality & Compliance Management
- Robin E. AbramsChief Legal Officer & Corporate Secretary
- Raymond M. JordtChief Business Officer
Dividend history
Dividends per share paid by Altimmune, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2017 | — | — | — | $875.9200 |
Key financials
Reported results for Altimmune, in USD.
- Market cap
- 396.8M
- Revenue (TTM)
- 31K
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 41K | -94.5M | -88.1M | |
| 20K | -103.2M | -95.1M | |
| 426K | -95.9M | -88.4M | |
| -68K | -87.7M | -84.7M |